These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 7184408)

  • 21. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.
    Burris HA; Hurwitz HI; Dees EC; Dowlati A; Blackwell KL; O'Neil B; Marcom PK; Ellis MJ; Overmoyer B; Jones SF; Harris JL; Smith DA; Koch KM; Stead A; Mangum S; Spector NL
    J Clin Oncol; 2005 Aug; 23(23):5305-13. PubMed ID: 15955900
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors.
    Siegel-Lakhai WS; Beijnen JH; Vervenne WL; Boot H; Keessen M; Versola M; Koch KM; Smith DA; Pandite L; Richel DJ; Schellens JH
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4495-502. PubMed ID: 17671135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The clinical phase I study of TNP-351. The TNP-351 Research Committee].
    Taguchi T; Niitani H; Furue H; Tsukagoshi S; Kanamaru R; Hasegawa K; Akazawa S; Yoneda S; Tominaga T; Sasaki T
    Gan To Kagaku Ryoho; 1995 Feb; 22(2):259-71. PubMed ID: 7857102
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
    Goss G; Siu LL; Gauthier I; Chen EX; Oza AM; Goel R; Maroun J; Powers J; Walsh W; Maclean M; Drolet DW; Rusk J; Seymour LK;
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):703-10. PubMed ID: 16528532
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors.
    Erlichman C; Hidalgo M; Boni JP; Martins P; Quinn SE; Zacharchuk C; Amorusi P; Adjei AA; Rowinsky EK
    J Clin Oncol; 2006 May; 24(15):2252-60. PubMed ID: 16710023
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors.
    Pitot HC; McElroy EA; Reid JM; Windebank AJ; Sloan JA; Erlichman C; Bagniewski PG; Walker DL; Rubin J; Goldberg RM; Adjei AA; Ames MM
    Clin Cancer Res; 1999 Mar; 5(3):525-31. PubMed ID: 10100703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors.
    Hoff PM; Saad ED; Ajani JA; Lassere Y; Wenske C; Medgyesy D; Dwivedy S; Russo M; Pazdur R
    Clin Cancer Res; 2003 Jan; 9(1):134-42. PubMed ID: 12538461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I trial of dihydroxyanthracenedione.
    Van Echo DA; Whitacre MY; Aisner J; Wiernik PH
    Cancer Treat Rep; 1981; 65(9-10):831-4. PubMed ID: 7273015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I clinical and pharmacokinetic study of Ro 31-7453 given as a 7- or 14-day oral twice daily schedule every 4 weeks in patients with solid tumors.
    Salazar R; Bissett D; Twelves C; Breimer L; DeMario M; Campbell S; Zhi J; Ritland S; Cassidy J
    Clin Cancer Res; 2004 Jul; 10(13):4374-82. PubMed ID: 15240525
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug.
    Hirata K; Horikoshi N; Aiba K; Okazaki M; Denno R; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Shirasaka T
    Clin Cancer Res; 1999 Aug; 5(8):2000-5. PubMed ID: 10473078
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.
    Hartung G; Stehle G; Sinn H; Wunder A; Schrenk HH; Heeger S; Kränzle M; Edler L; Frei E; Fiebig HH; Heene DL; Maier-Borst W; Queisser W
    Clin Cancer Res; 1999 Apr; 5(4):753-9. PubMed ID: 10213209
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Pharmacokinetic studies of a new fluorinated pyrimidine, 590-S (PH-FU), in human patients].
    Gan To Kagaku Ryoho; 1986 Jun; 13(6):2193-8. PubMed ID: 3717963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Phase I study of 5'-deoxy-5-fluorouridine (5'-DFUR)].
    Nakao I; Saito T; Kimura K; Wakui A; Yokoyama M; Kanamaru R; Furue H; Komita T; Ohta K; Murakami M
    Gan To Kagaku Ryoho; 1985 Oct; 12(10):2037-43. PubMed ID: 2932058
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Antitumor effects of p-aminobenzoic acid-N-xyloside Na--effects of single administration and combination with radiotherapy].
    Fukushima M; Ota K
    Gan To Kagaku Ryoho; 1982 Feb; 9(2):230-7. PubMed ID: 6985191
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I study of a new antitumor drug, 1-hexylcarbamoyl-5-fluorouracil (HCFU), administered orally: an HCFU clinical study group report.
    Koyama Y; Koyama Y
    Cancer Treat Rep; 1980; 64(8-9):861-7. PubMed ID: 7448823
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review of a new antimetabolic agent, 1,3-bis(tetrahydro-2-furanyl)-5-fluoro-2,4-pyrimidinedione (FD-1).
    Taguchi T
    Recent Results Cancer Res; 1980; 70():133-45. PubMed ID: 6766562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Use of ftorafur for the treatment of 3d-4th stage].
    Plaude RK; Osman VI; Tabachnik BI; Purinia IZh; Gutman EKh
    Vopr Onkol; 1975; 21(3):44-7. PubMed ID: 1093324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Phase II study of carmofur (HCFU) fine granules].
    Koyama Y
    Gan To Kagaku Ryoho; 1982 May; 9(5):906-14. PubMed ID: 7184433
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical phase I trial of a new anti-neoplastic drug--glyciphosphoramide].
    Sun Y
    Zhonghua Zhong Liu Za Zhi; 1984 Jul; 6(4):293-5. PubMed ID: 6525950
    [No Abstract]   [Full Text] [Related]  

  • 40. [Combinations drug therapy in solid tumors].
    Madrigal PL; Pérez Manga S; Pérez Gómez FJ
    Acta Oncol (Madr); 1975 May; 10(2):101-8. PubMed ID: 1211112
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.